Skip to main content

Table 1 Patients’ baseline characteristics: overall and according to tumor subtype

From: Immune characterization of breast cancer metastases: prognostic implications

  Population evaluated for TILs levels Population evaluated for CD8, FOXP3, PD-L1
Overall
n (%)
TN
n (%)
HER2+
n (%)
Overall
n (%)
TN
n (%)
HER2+
n (%)
Tot, n 94 43 51 64 28 36
Age at BC diagnosis, yrs. median (Q1–Q3) 49 (42–57) 51 (44–61) 46 (39–53) 51 (43–59) 54 (45–63) 47 (41–57)
Time to relapse, mos median (Q1–Q3) 27 (15–43) 19 (11–38) 31 (19–60) 27 (16–47) 18 (11–34) 31 (21–55)
Time from relapse to biopsy, mos median (Q1–Q3) 0 (0–5) 0 (0–2) 0 (0–11) 0 (0–6) 0 (0–2) 0 (0–15)
Histotype
 Ductal 81 (86) 36 (84) 43 (84) 56 (88) 22 (79) 34 (94)
 Lobular 5 (5) 1 (2) 4 (8) 2 (3) 1 (4) 1 (3)
 Other 8 (9) 6 (14) 2 (4) 6 (9) 5 (17) 1 (3)
Grade
 1–2 13 (14) 3 (7) 10 (20) 9 (14) 2 (7) 7 (19)
 3 78 (86%) 39 (93) 39 (80) 54 (86) 25 (83) 29 (81)
HR status
 HR+ 37 (39) 0 (0) 37 (72) 26 (41) 0 (0) 26 (72)
 HR- 57 (61%) 43 (100) 14 (28) 38 (59) 28 (100) 10 (28)
Stage at diagnosis
 I–II 50 (55) 27 (66 23 (46) 33 (52) 17 (63) 16 (44)
 III 38 (42) 13 (32) 25 (50) 27 (43) 9 (33) 18 (50)
 IV 3 (3) 1 (2) 2 (4) 3 (5) 1 (4) 2 (6)
Type of recurrent BC sample
 Locoregional relapse 40 (43) 23 (53) 17 (33) 25 (39) 13 (46) 12 (33)
 Distant relapse 54 (57) 20 (47) 34 (67) 39 (61) 15 (54) 24 (67)
Organ/site of biopsy
 Liver 24 (25) 5 (12) 19 (37) 15 (23) 4 (14) 11 (31)
 Skin 38 (40) 21 (49) 17 (33) 26 (41) 13 (47) 13 (36)
 Lung 12 (13) 7 (16) 5 (10) 8 (13) 4 (14) 4 (11)
 CNS 9 (10) 4 (9) 5 (10) 9 (14) 4 (14) 5 (14)
 Other 11 (12) 6 (14) 5 (10) 6 (9) 3 (11) 3 (8)
Neo/adjuvant chemotherapy
 No 13 (14) 3 (7) 10 (20) 9 (14) 3 (11) 6 (17)
 Yes 81 (86) 40 (93) 41 (80) 55 (86) 25 (89) 30 (83)
Neo/adjuvant trastuzumab
 No 21 (41) 12 (33)
 Yes 30 (59) 24 (67)
Pre-biopsy systemic treatment for MBC
 No 70 (74) 36 (88) 34 (67) 46 (72) 25 (89) 21 (58)
 Yes 24 (26) 7 (17) 17 (33) 18 (28) 3 (11) 15 (42)
  1. Abbreviations: TILs tumor-infiltrating lymphocytes, TN triple negative, HER2 human epidermal growth factor receptor-2, n number, tot total, BC breast cancer, yrs years, mos months, Q1 first quartile, Q3 third quartile, HR hormone receptor, CNS central nervous system, MBC metastatic breast cancer